Brief: Grand Pharmaceutical's Innovative Therapeutic Tumor Vaccine Arc01 Was Accepted By NMPA Of China
02/11/2023 12:31
Nov 2 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* GROUP'S INNOVATIVE THERAPEUTIC TUMOR VACCINE ARC01 WAS
ACCEPTED
BY NMPA OF CHINA
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement